key: cord-0962629-rzn0c3da
authors: Berger, A.; Ngo Nsoga, M.-T.; Perez Rodriguez, F. J.; Abi Aad, Y.; Sattonnet, P.; Gayet-Ageron, A.; Jaksic, C.; Torriani, G.; Boehm, E.; Kronig, I.; Sacks, J. A.; de Vos, M.; Jacquerioz-Bausch, F.; Chappuis, F.; Kaiser, L.; Schibler, M.; Eckerle, I.
title: Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers
date: 2020-11-23
journal: nan
DOI: 10.1101/2020.11.20.20235341
sha: 17bcca3034bc8494deb63e25bea0ff3efe17bd28
doc_id: 962629
cord_uid: rzn0c3da

Background. Antigen-detecting rapid diagnostic tests for SARS-CoV-2 offer new opportunities for the quick and laboratory-independent identification of infected individuals for control of the SARS-CoV-2 pandemic. Methods. We performed a prospective, single-center, point of care validation of two antigen-detecting rapid diagnostic tests (Ag-RDT) in comparison to RT-PCR on nasopharyngeal swabs. Findings. Between October 9th and 23rd, 2020, 1064 participants were enrolled. The PanbioTM Covid-19 Ag Rapid Test device (Abbott) was validated in 535 participants, with 106 positive Ag-RDT results out of 124 positive RT-PCR individuals, yielding a sensitivity of 85.5% (95% CI: 78.0-91.2). Specificity was 100.0% (95% CI: 99.1-100) in 411 RT-PCR negative individuals. The Standard Q Ag-RDT (SD Biosensor, Roche) was validated in 529 participants, with 170 positive Ag-RDT results out of 191 positive RT-PCR individuals, yielding a sensitivity of 89.0% (95%CI: 83.7-93.1). One false positive result was obtained in 338 RT-PCR negative individuals, yielding a specificity of 99.7% (95%CI: 98.4-100). For individuals presenting with fever 1-5 days post symptom onset, combined Ag-RDT sensitivity was above 95%. Interpretation. We provide an independent validation of two widely available commercial Ag-RDTs, both meeting WHO criteria of at least 80% sensitivity and at least 97% specificity. Although less sensitive than RT-PCR, these assays could be beneficial due to their rapid results, ease of use, and independence from existing laboratory structures. Testing criteria focusing on patients with typical symptoms in their early symptomatic period onset could further increase diagnostic value.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint RDTs, both meeting WHO criteria of ≥80% sensitivity and ≥97% specificity. Although less 48 sensitive than RT-PCR, these assays could be beneficial due to their rapid results, ease of use, 49 and independence from existing laboratory structures. Testing criteria focusing on patients 50 with typical symptoms in their early symptomatic period onset could further increase 51 diagnostic value. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020.

The 2019 novel coronavirus (SARS-CoV-2) which causes Coronavirus Disease 19 (COVID-19), 56 has led to an unprecedented pandemic and a global public health crisis. Developing diagnostic 57 strategies that are easily accessible, provide rapid results and are of low cost to allow use in 58 resource limited settings is critical in order to control the pandemic. While RT-PCR based 59 detection remains the standard for the detection of emerging respiratory viruses (1,2), the 60 global need for virus detection methods has fueled research and development of diagnostic 61 tests, including as Antigen-detecting rapid diagnostic tests (Ag-RDT), that can be performed at 62 the point of care (POC) (3). 63

Such laboratory-independent tests could be key to detecting acutely infected and especially 64 contagious individuals, allowing for control of the pandemic by quickly isolating individuals 65 during their contagious period to prevent further transmission. These tests can also help 66 overcome bottlenecks such as overwhelmed diagnostic laboratories and global shortages of 67 PCR reagents, while being affordable (4). Ag-RDTs could enable mass screenings, which allow 68 estimation of active infection prevalence, and confirming a COVID-19 diagnosis especially in 69 settings where results are not available in a timely manner (5). Given that viral load, as 70 measured by RNA levels, peaks near symptom onset (6-8) and contagiousness can begin days 71 before symptom onset (9,10), it is expected that RDTs would have the highest sensitivity (SN) 72 in those infected individuals that are most contagious. However, reported SNs of Ag-RDTs vary 73 widely, and manufacturer reported SNs are often substantially higher than the SNs reported 74 by independent assessments (11). The World Health Organisation (WHO) has published an Ag-75 RDT target product profile, aiming at SN ≥80% and a specificity (SP) of ≥97% (5,12). Thus, we 76 sought to evaluate the performance of two commercially available Ag-RDTs through a 77 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint 5 prospective, single-center POC validation in comparison to RT-PCR for detecting SARS-CoV-2 78 using nasopharyngeal swabs (NPS) under real-life conditions. 79 80

Ethics 82

The study was approved by the Cantonal ethics committee (Nr. 2020-02323). All study 83 participants and/or their legal guardians provided written informed consent. 84

Setting 86

The study was performed in two geographically different testing centres in Geneva, run by our 87 institution, the Geneva University Hospitals: one adjacent to the University hospital ("Sector 88 E") and the other located in another part of the city ("Sector G") between October 9 th and 89

October 23 rd , 2020. Both centres are supervised by the same team, and did not differ in their 90 infrastructure, so we analyzed them as a single centre study. 91 92

The primary objective of this prospective study was to assess the diagnostic accuracy (SN and 94 SP) of the Ag-RDTs compared to the reference RT-PCR. All individuals presenting to the testing 95 centres were informed about the study and enrolled if they consented. Participants were ≥16 96 years of age, with suspected SARS-CoV-2 infection according to the local governmental testing 97 criteria. This included suggestive symptoms for COVID-19 and/or recent exposure to a SARS-98

CoV-2 positive person. Asymptomatic individuals were included if they were notified by the 99

Swiss COVID-19 app about a contact offering the option to get tested on day 5 after contact, 100 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint or if they received a notification from local health authorities (screening of people with high 101 risk exposure in a cluster). 102 103

For each participant, two NPS were collected. The first was a standard flocked swab placed in 105 viral transport media (VTM), used routinely for viral genome detection by RT-PCR. The second 106 NPS, provided in the Ag-RDT kit, was obtained from the contralateral nostril and was 107 performed as recommended by the manufacturer. Both swabs were taken by the same 108 trained nurse. All Ag-RDTs were performed immediately at the sample collection site. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint

The two validated Ag-RDTs were Panbio Covid-19 Ag Rapid Test device (Abbott Rapid 126 Diagnostics) and Standard Q (SD Biosensor, Roche). Both Ag-RDTs were used as recommended 127 by the manufacturers, using only materials provided by the manufacturers in the kits. Both 128 assays were manually read, with two individuals reading the results separately after the 

All participants were tested by a dual target RT-PCR assay for SARS-CoV-2 (Cobas, Roche) using 135 NPS in 3mL VTM. For further analysis, only cycle threshold (Ct) values for the E-gene were 136 used. For calculation of viral loads (VL) as SARS-CoV-2 genome copy numbers per mL, a 137 standard curve was obtained by using a quantified supernatant from a cell culture isolate of 138 SARS-CoV-2. All VLs were calculated from the Ct-values, according to log10 SARS-CoV-2 RNA 139 copies/ml = (Ct-44.5)/-3.3372 for Cobas (13, 14) . 140 141

We enrolled all patients who met the SARS-CoV-2 testing criteria, over a 2-week period. During 143 the first and second week, 529 and 535 patients were enrolled respectively. The target sample 144 size was 530, as it would have sufficient power to generate a 95% confidence interval (CI) with 145 a lower bound above the WHO target of 80%, if the prevalence was 25% and the measured SP 146 was ≥87.5%. 147 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint 8 All continuous variables were presented by their mean ±standard deviation (SD) and median 148 (interquartile range, IQR), categorical variables were presented by their frequencies and 149 relative proportions. For comparisons of continuous variables, we used a nonparametric 150

Mann-Whitney test due to small sizes; for comparisons of categorical variables, we either 151 performed Chi 2 or Fischer's exact tests, depending on applicability. 152

To enable Ag-RDT result combination, we performed a Bayesian t-test on their sensitivities 153 and specificities. To be able to conduct the t-test, the confidence intervals of both sensitivities 154 and specificities were converted into standard deviation to allow for the t-test to be 155 conducted. The test computes a Bayesian Factor (BF) that allows comparison of the probability 156 of observing our data under H0 (both tests are equal in term of SN and SP) and H1 (both tests 157 are different). All analyses were performed using STATA version intercooled 16 (Stata Corp., 158

College Station, TX, USA). Statistical significance was defined as p<0.05 (two-sided). 159 160

Between October 9 th and October 23 rd , 2020, 1064 participants were enrolled and included in 162 the analysis. 535 participants were tested with the Panbio Ag-RDT from October 09 th to 16 th 163 and 529 participants were tested with the Standard Q Ag-RDT from October 19 th to 23 rd , 2020. 164

The demographic and clinical characteristics of the study population are shown in Table 1 . The 165 mean age of the study participants was 34.9 years (SD ±10.9) with 53.8% being female. The 166 mean DPOS to testing was 2.7 (SD ±1day). Overall, 29.6% of participants were positive by RT-167 PCR with a mean Ct-value of 22.5 (SD ±5.1), corresponding to a VL of 1.8E7 SARS-CoV-2 168 copies/mL. Most patients (97.8%) were symptomatic upon presentation at the testing centre, 169

with only 3 reporting no symptoms. Symptoms information was missing for 4 patients. The 170 study population tested with the Standard Q vs. was younger than that tested with the Panbio 171 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint assay (34.9 ±10.9 vs 38.5 ±13.6 years, respectively, p<0.001) and DPOS differed slightly 172

(2.9±1.5 vs. 2.6±2.0 days, respectively, p=0.0125). Ct-values did not differ significantly 173 between the two groups (p=0.450): 22.6 (SD ±4.9) in the Standard Q group vs. 22.4 (SD ±5.4) 174

in the Panbio group, corresponding to 1.7E7 and 1.9E7 SARS-CoV-2 RNA copies/mL, 175

respectively. The RT-PCR positivity rate was 23.2% and 36.1% for the population tested with 176 the Panbio and the Standard Q, respectively, corresponding to an increase in the overall PCR 177 positivity rate and reflecting the rapidly increasing local incidence during the time of this 178 study. 179

The overall test performance for the Standard Q was 89.0% SN (95%CI: 83.7-93.1) and 99.7% 180 SP (95%CI: 98.4-100%). The overall test performance for the Panbio assay was 85.5% SN 181 (95%CI: 78.0-91.2) and 100% SP (95%CI: 99.1-100) ( Table 2) . We compared SN and SP between the two Ag-RDTs and concluded that we could accept, with 191 high probabilities, (respectively likelihood ratio of BF01=10.2 and 11.9) the hypothesis of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint sample size was small. No difference was seen in patients with or without contact with a 220 recently positive case (p=0.065). We further analysed by DPOS, and found that the highest SN 221 was seen in patients with fever/chills and presenting between 1 and 5 DPOS, at 95.7% SN 222 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint

This study provides an independent, POC validation of two commercial Ag-RDTs in comparison 225 to SARS-CoV-2 RT-PCR and according to demographic and clinical information. This combined 226 validation of two similar assays provides performance data in a real-life high incidence test 227 setting with an approach aimed at an immediate implementation solution. 228

Both RDTs performed well with an overall SN of 87.6% (95%CI: 83.5-91) and a very high SP of 229 99.9% (95%CI: 99.3-100) in our test setting during a time of very high SARS-CoV-2 weekly 230 incidence (375/100,000 to 824/100,000 inhabitants) and a SARS-CoV-2 RT-PCR positivity rate 231

19 symptoms. Importantly we highlight that on day 0 of symptoms, the SN may be lower than 233 during the subsequent days, and as expected, the sensitivity drops rapidly when the Ct-values 234 increase above a threshold of 30, mostly after 6-7 days. These results suggest that with 235 increasing availability, Ag-RDTs can enable rapid and reliable identification of SARS-CoV-2 236 cases and hold a promise for more efficient control of the current pandemic, independent of 237 existing diagnostic structures. 238

The highest VL and thus the highest SARS-CoV-2 transmission probability occurs within the 239 first week of symptom onset, with VLs peaking shortly before or at the time of symptom onset 240 (6). Culturable virus has been predominantly found in the first week after symptom onset, up 241 to a VL in the range of 1E6 copies/ml (14) (15) (16) (17) . This cut-off was also chosen by WHO in their 242

Ag-RDT target product profile guide for SARS-CoV-2 diagnostics (12). The SN of the Ag-RDTs 243 validated here, for patients presenting with a VL compatible with contagiousness, was 95.7%. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint Our findings at the POC are in line with other validations performed across countries and at 247 different SARS-CoV-2 prevalence, although study designs and specimens used varied 248 considerably between studies. Standard Q was reported to have SNs between 70.6-88.7%, 249

while SP remained high throughout these studies between 97.6-100% (18-24). A clinical study 250 performed similarly to ours in a much lower-incidence setting (<1% RT-PCR positivity rate), 251 found a SN/SP of 76.6%/100%, using a mixture of NPS and combined oro-and naso-pharyngeal is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint

We did not find any validation of Ag-RDTs that has analyzed SN based on type of symptoms, 271 which could be an additional factor for testing algorithms. Our data suggests that the best SN 272 is found in symptomatic individuals with symptoms suggestive of COVID-19, early in the 273 disease between day 1 and 5. The presence of only non-specific symptoms of respiratory 274 illness corresponded to lower SN, however, few study participants had no COVID-19 specific 275 symptoms at all. 276

Our study has several strengths. The Ag-RDTs were performed at the POC in parallel to RT-277 PCR, and is one of the largest in terms of RT-PCR positive individuals. The test population was 278 mainly young adults without comorbidities, who mostly had typical COVID-19 symptoms that 279 were still mild enough not to require hospitalization. This represents a population screened 280 for public health intervention, and not for diagnostic purposes in a hospital setting; and the 281 majority of SARS-CoV-2 infected individuals at the current phase of the epidemic in the 282 community, which is an important group for early identification to limit viral transmission. 283

Thus, the results of our study support implementing the Ag-RDTs in a decentralized manner 284 for community testing, which could significantly alleviate the burden on diagnostic 285 laboratories and hospital staff. 286

Although Ag-RDTs are less sensitive than RT-PCR and, in our study, false-negative Ag-RDT 287 results were also seen in patients with high VL, the public health benefit of quickly identifying is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint be used for rule-out purposes or for any kind of reduced infection prevention measures. The 295 lower SN found at 0 DPOS was probably due to a still increasing VL. Re-testing with an Ag-RDT 296 or RT-PCR, in case of persisting symptoms, could overcome this limitation. During the time this study was conducted, the Canton of Geneva was experiencing a severe 302 second wave of SARS-CoV-2 infections, with a very high incidence as well as high RT-PCR 303 positivity rates, thus extrapolating the findings of our study to low prevalence settings must 304 be done with caution. Furthermore, our study population consisted mainly of young 305 symptomatic individuals in an outpatient setting, thus diagnostic performance in other groups 306 needs further validation. All diagnostic testing was performed on NPS collected by trained 307 nurses, thus the use of the test with other materials (e.g. anterior nares swabs) or in other 308 settings (e.g. self-testing) needs to be further validated, however a first study on anterior nasal 309 samples showed promising results (30) . Due to logistical and ethical reasons, we were not able 310 to perform paired comparisons of both Ag-RDTs at the same time by taking three separate 311 NPS, which would have helped to control for prevalence variation and inter-cohort variability. 312

Nonetheless, we used robust methods to confirm that the SN and SP of both Ag-RDTs was 313 equivalent, and further combined results of both Ag-RDTs. 314

In conclusion, we show good diagnostic accuracy of both Ag-RDTs, especially for rule-in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint structures make these Ag-RDTs promising tools for SARS-CoV-2 infection control in the 319 community. 320 321

We thank all nurses and staff at the testing Centre Sectors of our institution as well as the 323 patients for their willingness to participate in the study. We thank Catia Machado-Delgado for 324 excellent technical assistance and Stéphanie Baggio for help with data analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint Tables  416   Table 1 

Positivity rate at the time of study for Standard Q was 36.1% and at the time of study for Panbio was 23.2%.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 23, 2020. ; https://doi.org/10.1101/2020.11.20.20235341 doi: medRxiv preprint

Detection of a novel human 333 coronavirus by real-time reverse-transcription polymerase chain reaction

Coronavirus in Patients with Severe Acute Respiratory Syndrome

The explosion of new coronavirus tests that could help to end the pandemic

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

Temporal dynamics in viral shedding and 346 transmissibility of COVID-19

SARS-CoV-2 Viral Load in Upper Respiratory 348 Specimens of Infected Patients

SARS-CoV-2 detection, viral load and 350 infectivity over the course of an infection

The Incubation Period of Coronavirus 352 Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann 353 Intern Med

Inferred duration of infectious period 355 of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and 356 symptomatic COVID-19 cases

Group TEC-19 microbiological laboratories. Meta-analysis of the 358 clinical performance of commercial SARS-CoV-2 nucleic acid, antigen and antibody tests up to 22

COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic

SARS-CoV-2 viral load in the upper 364 respiratory tract of children and adults with early acute COVID-19

Culture-Competent SARS-CoV-2 in Nasopharynx of 366

Symptomatic Neonates, Children, and Adolescents. Emerg Infect Dis

Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series

Evaluation of the 376 accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics 377 for SARS-CoV-2. medRxiv

Urgent need of rapid tests for SARS 379

CoV-2 antigen detection: Evaluation of the SD-Biosensor antigen test for SARS-CoV-2

Rapid chromatographic immunoassay-382 based evaluation of COVID-19: A cross-sectional, diagnostic test accuracy study & its implications for 383

COVID-19 management in India. The Indian journal of medical research

FIND Evaluation of SD Biosensor, Inc. STANDARD TM Q COVID-19 Ag FIA External Report. 2020. 386 FIND

SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis 389 of COVID-19 in Thailand

Field Evaluation of the 391 Performance of a SARS-CoV-2 Antigen Rapid Diagnostic Test in Uganda using Nasopharyngeal Samples. 392 International Journal of Infectious Diseases

Real-life validation of 394 the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of 395 potential SARS-CoV-2 infection. medRxiv

Analytical and Clinical 397 Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. medRxiv

Field evaluation of a rapid 400 antigen test (PanbioTM COVID-19 Ag Rapid Test Device) for the diagnosis of COVID-19 in primary 401 healthcare centers. medRxiv

Panbio antigen 403 rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms

rapid antigen detection test device for the screening of patients with Covid-19

Test sensitivity is secondary to 409 frequency and turnaround time for COVID-19 surveillance

SARS-CoV-2 antigen-detecting rapid test with self-collected anterior nasal swab versus professional